Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Current Diabetes Reviews
  4. Volume 21, Issue 5
  5. Article
Volume 21, Issue 5
  • ISSN: 1573-3998
  • E-ISSN: 1875-6417

Abstract

Introduction

Diabetes Mellitus (DM) is a metabolic disorder characterized by persistent hyperglycemia and/or insulin resistance. If left uncontrolled, it can lead to a combination of cardiac and renal alterations known as cardiorenal syndrome. Additionally, oxidative stress and inflammation contribute to tissue damage, thereby reducing the life expectancy of individuals with diabetes.

Aim

The aim of this study was to identify early molecular markers associated with cardiorenal syndrome, oxidative stress, and inflammation, and to investigate their correlation with the duration of exposure to DM.

Methods

An experimental DM model was employed using Wistar rats. The rats were divided into four groups: diabetic rats at 7 days (DM7), diabetic rats at 30 days (DM30), control sham at 7 days (CS7), and control sham at 30 days (CS30). Blood and brain tissue from the brainstem region were collected at 7 and 30 days after confirming DM induction. Gene expression analysis of , and was performed.

Results

The analysis revealed lower expression values of in the brainstem tissue of the DM7 group compared to the NDS7 group. Moreover, diabetic animals exhibited statistically lower levels of in their peripheral blood compared to the control animals.

Conclusion

This study concluded that DM alters the oxidative balance in the brainstem after 7 days of DM induction, resulting in lower expression levels. Although some genes did not show statistical differences after 30 days of DM induction, other genes exhibited no expression values, indicating possible gene silencing. The study identified an imbalance in the studied pathways and concluded that the organism undergoes a compensatory state in response to the initial metabolic alterations caused by DM.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cdr/10.2174/0115733998264880230919062657
2024-06-20
2025-01-18

  • From This Site

    /content/journals/cdr/10.2174/0115733998264880230919062657
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. HadjiphilippouS. KonS.P. Cardiorenal syndrome: Review of our current understanding.J. R. Soc. Med.20161091121710.1177/014107681561609126609123
     [Google Scholar]
  2. JeongS. ChoS. KongS.Y. Effect of income level on stroke incidence and the mediated effect of simultaneous diagnosis of metabolic syndrome diseases; a nationwide cohort study in South Korea.Diabetol. Metab. Syndr.202214111010.1186/s13098‑022‑00882‑135941692
     [Google Scholar]
  3. RangaswamiJ. BhallaV. BlairJ.E.A. Cardiorenal syndrome: Classification, pathophysiology, diagnosis, and treatment strategies: A Scientific statement from the american heart association.Circulation201913916e840e87810.1161/CIR.000000000000066430852913
     [Google Scholar]
  4. MandaviaC.H. AroorA.R. DeMarcoV.G. SowersJ.R. Molecular and metabolic mechanisms of cardiac dysfunction in diabetes.Life Sci.2013921160160810.1016/j.lfs.2012.10.02823147391
     [Google Scholar]
  5. ChanJ.C.Y. KnudsonO. WuF. MorserJ. DoleW.P. WuQ. Hypertension in mice lacking the proatrial natriuretic peptide convertase corin.Proc. Natl. Acad. Sci.2005102378579010.1073/pnas.040723410215637153
     [Google Scholar]
  6. AkashiY.J. SpringerJ. LainscakM. AnkerS.D. Atrial natriuretic peptide and related peptides.Clin. Chem. Lab. Med.200745101259126710.1515/CCLM.2007.27417663625
     [Google Scholar]
  7. Del RyS. CabiatiM. ClericoA. Natriuretic peptide system and the heart.Front. Horm. Res.20144313414310.1159/00036059724943304
     [Google Scholar]
  8. BieP. Natriuretic peptides and normal body fluid regulation.Compr. Physiol.2018831211124910.1002/cphy.c18000229978892
     [Google Scholar]
  9. EstradaV. TéllezM.J. MoyaJ. Fernández-DurangoR. EgidoJ. Fernández CruzA. High plasma levels of endothelin-1 and atrial natriuretic peptide in patients with acute ischemic stroke.Am. J. Hypertens.19947121085108910.1093/ajh/7.12.10857702803
     [Google Scholar]
  10. FengY. WangD. BiH. ZhangH. The role of natriuretic peptides in diabetes and its complications.Biomed. Pharmacother.2016841826183210.1016/j.biopha.2016.10.08927832993
     [Google Scholar]
  11. BerezinA.E. BerezinA.A. Circulating cardiac biomarkers in diabetes mellitus: A new dawn for risk stratification-A narrative review.Diabetes Ther.20201161271129110.1007/s13300‑020‑00835‑932430864
     [Google Scholar]
  12. BenomarK. EspiardS. LoyerC. JanninA. VantyghemM.C. (Atrial natriuretic hormones and metabolic syndrome: Recent advances).Presse Med.201847211612410.1016/j.lpm.2017.12.00229496376
     [Google Scholar]
  13. YamadaT. NakaoK. ItohH. Intracerebroventricular injection of brain natriuretic peptide inhibits vasopressin secretion in conscious rats.Neurosci. Lett.1988951-322322810.1016/0304‑3940(88)90661‑13226610
     [Google Scholar]
  14. Villacorta JúniorH. MesquitaE.T. (Clinical applications of B-type natriuretic peptide assays).Arq. Bras. Cardiol.200686425125516680288
     [Google Scholar]
  15. VickeryS. PriceC.P. JohnR.I. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: Relationship to renal function and left ventricular hypertrophy.Am. J. Kidney Dis.200546461062010.1053/j.ajkd.2005.06.01716183415
     [Google Scholar]
  16. Miranda-DíazA.G. Pazarín-VillaseñorL. Yanowsky-EscatellF.G. Andrade-SierraJ. Oxidative stress in diabetic nephropathy with early chronic kidney disease.J. Diabetes Res.201620161710.1155/2016/704723827525285
     [Google Scholar]
  17. CloughG.F. KuligaK.Z. ChipperfieldA.J. Flow motion dynamics of microvascular blood flow and oxygenation: Evidence of adaptive changes in obesity and type 2 diabetes mellitus/insulin resistance.Microcirculation2017242e1233110.1111/micc.1233127809397
     [Google Scholar]
  18. YaribeygiH. ButlerA.E. BarretoG.E. SahebkarA. Antioxidative potential of antidiabetic agents: A possible protective mechanism against vascular complications in diabetic patients.J. Cell. Physiol.201923432436244610.1002/jcp.2727830191997
     [Google Scholar]
  19. RehmanK. AkashM.S.H. LiaqatA. KamalS. QadirM.I. RasulA. Role of interleukin-6 in development of insulin resistance and type 2 diabetes mellitus.Crit. Rev. Eukaryot. Gene Expr.201727322923610.1615/CritRevEukaryotGeneExpr.201701971229199608
     [Google Scholar]
  20. AhmedS. MundheN. BorgohainM. Diosmin modulates the NF-kB signal transduction pathways and downregulation of various oxidative stress markers in alloxan-induced diabetic nephropathy.Inflammation20163951783179710.1007/s10753‑016‑0413‑427492452
     [Google Scholar]
  21. GhobadiH. AslaniM.R. HosseinianA. FarzanehE. The correlation of serum brain natriuretic peptide and interleukin-6 with quality of life using the chronic obstructive pulmonary disease assessment test.Med. Princ. Pract.201726650951510.1159/00048490029131048
     [Google Scholar]
  22. KirchnerB. PaulV. RiedmaierI. PfafflM.W. mRNA and microRNA purity and integrity: The key to success in expression profiling.Methods Mol. Biol.20141160435310.1007/978‑1‑4939‑0733‑5_524740220
     [Google Scholar]
  23. LiH. LiuX. RenZ. Effects of diabetic hyperglycemia on central Ang-(1-7)-Mas-R-nNOS pathways in spontaneously hypertensive rats.Cell. Physiol. Biochem.20164051186119710.1159/00045317227960152
     [Google Scholar]
  24. LuH.L. HuangX. WuY.S. Gastric nNOS reduction accompanied by natriuretic peptides signaling pathway upregulation in diabetic mice.World J. Gastroenterol.201420164626463510.3748/wjg.v20.i16.462624782615
     [Google Scholar]
  25. VolpeM. CarnovaliM. MastromarinoV. The natriuretic peptides system in the pathophysiology of heart failure: From molecular basis to treatment.Clin. Sci.20151302577710.1042/CS2015046926637405
     [Google Scholar]
  26. OhishiM. Hypertension with diabetes mellitus: Physiology and pathology.Hypertens. Res.201841638939310.1038/s41440‑018‑0034‑429556093
     [Google Scholar]
  27. Rangel SilvaresR. Nunes Goulart da Silva PereiraE. Eduardo Ilaquita FloresE. High-fat diet-induced kidney alterations in rats with metabolic syndrome: Endothelial dysfunction and decreased antioxidant defense.Diabetes Metab. Syndr. Obes.2019121773178110.2147/DMSO.S21125331564943
     [Google Scholar]
  28. BarbosaJ.H. OliveiraS.L. SearaL.T. The role of advanced glycation end-products (AGEs) in the development of vascular diabetic complications.Arq. Bras. Endocrinol. Metabol200852694095010.1590/S0004‑2730200800060000518820805
     [Google Scholar]
  29. RomS. Zuluaga-RamirezV. GajghateS. Hyperglycemia-driven neuroinflammation compromises bbb leading to memory loss in both Diabetes Mellitus (DM) type 1 and type 2 mouse models.Mol. Neurobiol.20195631883189610.1007/s12035‑018‑1195‑529974394
     [Google Scholar]
  30. KimuraH. KamiyamaK. ImamotoT. Fenofibrate reduces cisplatin-induced apoptosis by inhibiting the p53/Puma/Caspase-9 pathway and the MAPK/Caspase-8 pathway rather than by promoting autophagy in murine renal proximal tubular cells.Biochem. Biophys. Rep.20223010123710.1016/j.bbrep.2022.10123735252595
     [Google Scholar]
  31. FehlmannT. LehallierB. SchaumN. Common diseases alter the physiological age-related blood microRNA profile.Nat. Commun.2020111595810.1038/s41467‑020‑19665‑133235214
     [Google Scholar]
  32. TakahashiM. EdaA. FukushimaT. HohjohH. Reduction of type IV collagen by upregulated miR-29 in normal elderly mouse and klotho-deficient, senescence-model mouse.PLoS One2012711e4897410.1371/journal.pone.004897423139829
     [Google Scholar]
  33. HeinemannF.M. JindraP.T. BockmeyerC.L. Glomerulocapillary miRNA response to HLA-class I antibody in vitro and in vivo.Sci. Rep.2017711455410.1038/s41598‑017‑14674‑529109529
     [Google Scholar]
  34. ZhaoW. MengX. LiangJ. Analysis of circRNA‐mRNA expression profiles and functional enrichment in diabetes mellitus based on high throughput sequencing.Int. Wound J.20221951253126210.1111/iwj.1383835504843
     [Google Scholar]
/content/journals/cdr/10.2174/0115733998264880230919062657
Loading
Downregulation of Tnf-α and Cat Expression in a Wistar Rat Diabetic Model during Diabetes Onset
Curr. Diabetes Rev. 21, E200624231125 (2025); https://doi.org/10.2174/0115733998264880230919062657
/content/journals/cdr/10.2174/0115733998264880230919062657
/content/journals/cdr/10.2174/0115733998264880230919062657
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): biomarkers; cardiorenal syndrome; Diabetes mellitus; insulin resistance; metabolic syndrome; natriuretic peptides

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test